Panelists on PharmTech AI Pulse Check debate SURPASS, a new digital-twin trial program, regulatory acceptance, and the data-cleanup burden it will create.
|Articles|March 2, 2003
- Pharmaceutical Technology-03-02-2003
- Volume 27
- Issue 3
Effects of Breadfruit and Cocoyam Starch Mucilage Binders. On Disintegration and Dissolution Behaviors of Paracetamol Tablet Formulations.
Author(s)A.S. Adebayo, PhD
Binder properties of mucilage of starches extracted from breadfruit and cocoyam were investigated in paracetamol tablet formulations using tablet physical properties, disintegration times, and dissolution rates as assessment parameters.
Advertisement
Articles in this issue
over 23 years ago
The Clarification of Bioreactor Cell Cultures for Biopharmaceuticalsover 23 years ago
Standards for Supplementsover 23 years ago
Concept Paper Discusses Update of Aspetic Processing Guidelinesover 23 years ago
Outsourcing Outlook March 2003over 23 years ago
March 2003Advertisement
Related to this article
Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
Germany is home to several prominent pharma companies and more than 1000 innovative biotechs.
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Germany’s Medical Biotechnology Sector is Flourishing
2
Formulation Strategies for Next-Generation Multiagonists
3
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
4
First-in-Human Trial Speed: Why FDA Trails China
5